(Q39226360)

English

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

scientific article published on 21 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

10 September 2017

0 references

author name string

Jordi Rodon

1

1 reference

Europe PubMed Central

10 September 2017

Irene Braña

2

1 reference

Europe PubMed Central

10 September 2017

Lillian L Siu

3

1 reference

Europe PubMed Central

10 September 2017

Maja J De Jonge

4

1 reference

Europe PubMed Central

10 September 2017

Natasha Homji

5

1 reference

Europe PubMed Central

10 September 2017

David Mills

6

1 reference

Europe PubMed Central

10 September 2017

Emmanuelle Di Tomaso

7

1 reference

Europe PubMed Central

10 September 2017

Celine Sarr

8

1 reference

Europe PubMed Central

10 September 2017

Lucia Trandafir

9

1 reference

Europe PubMed Central

10 September 2017

Cristian Massacesi

10

1 reference

Europe PubMed Central

10 September 2017

Ferry Eskens

11

1 reference

Europe PubMed Central

10 September 2017

Johanna C Bendell

12

1 reference

Europe PubMed Central

10 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 March 2014

1 reference

Europe PubMed Central

10 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

10 September 2017

32

1 reference

Europe PubMed Central

10 September 2017

670-681

1 reference

Europe PubMed Central

10 September 2017

4

1 reference

Europe PubMed Central

10 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-014-0082-9

0 references

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Induction of Akt activity by chemotherapy confers acquired resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

A brief measure for assessing generalized anxiety disorder: the GAD-7.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

The PHQ-9: validity of a brief depression severity measure

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Cancer phase I clinical trials: efficient dose escalation with overdose control.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Critical nodes in signalling pathways: insights into insulin action

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

PTEN-deficient cancers depend on PIK3CB.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0082-9

21 January 2018

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24652201

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-014-0082-9

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39226360&oldid=2088806122"